Renaissance Capital logo

SELB News

Nanoparticle biotech Selecta Biosciences prices upsized IPO at $14, the low end of the range

SELB

Selecta Biosciences, which is developing nanoparticles that modulate the immune system to enhance biologics, raised $70 million by offering 5 million shares at $14. It had originally planned to raise $64 million by offering 4.25 million shares at $14 to $16. Selecta Biosciences plans to list on the Nasdaq under the symbol SELB. UBS Investment Bank and Stifel acted as lead managers...read more

US IPO Week Ahead: IPO market discovers whether unicorns can fly with tech firm Twilio

TWLO

All eyes are on communications tech IPO Twilio (TWLO). The reception of its offering will send a message to other tech unicorns that have been called out for sky-high valuations. It is the first Silicon Valley "unicorn" to go public since Square (SQ; +1%)...read more

Are nanoparticles the next big thing? Selecta Biosciences sets terms for $64 million IPO

SELB

Selecta Biosciences, which is developing nanoparticles that modulate the immune system to enhance drugs, announced terms for its IPO on Wednesday. The Watertown, MA-based company plans to raise $64 million by offering 4.3 million shares at a price range of $14 to $16. Insiders intend to purchase $40 million worth of shares (63%) in the offering. At the midpoint of the proposed...read more

Think nano: Selecta Biosciences files for a $75 million IPO to fund nanoparticle immunotherapies

SELB

Selecta Biosciences, which is developing immunotherapies based on its proprietary nanoparticle platform, filed on Tuesday with the SEC to raise up to $75 million in an initial public offering. The Watertown, MA-based company was founded in 2007 and plans to list on the Nasdaq under the symbol SELB. Selecta Biosciences filed confidentially on November 24, 2015. UBS Investment...read more

Archived Headlines